Treatment of hepatitis C virus infection in the future

Clinical and Translational Medicine

Table 3 New standard of care treatment with boceprevir for chronic hepatitis C patients

References	G	Number of patients	Naïve or re-treatment	Formula of therapy, and duration of treatment (weeks)	SVR rates (%)	Notes
[41]	G1	363	naive	PR48	38	SPRINT-2
		368	naive	PR4+BocPR24+PR22	63
		366	naive	PR4+BocPR44	66
[42]	G1	80	re-treatment	PR48	21	HCV RESPOND-2
		162	re-treatment	PR4+BocPR24+PR22	59
		161	re-treatment	PR4+BocPR44	66

PR48 group received peginterferon alfa-2a and ribavirin for 48 weeks; T12PR12, T12PR24 or T12 PR48 group received telaprevir for 12 weeks and peginterferon alfa-2a and ribavirin for 12, 24 or 48 weeks, respectively; T12P12 group received telaprevir and ribavirin for 12 weeks; T24P24 group received telaprevir and peginterferon alfa-2a for 24 weeks; RGT, response-guided therapy; Boc, boceprevir.